🧬 BioMed Pulse · 2026-10-26 02:01 UTC
BIOMED PULSE
Monday, October 26, 2026 | Your daily briefing on longevity, viruses, and new cures
⚡ TL;DR
The Bundibugyo virus Ebola outbreak in the DRC has now spread to Kenya and Nigeria, marking the largest Ebola outbreak ever recorded and the most rapidly expanding in history.
Overall mood: CRITICAL on the outbreak front, CAUTIOUSLY ACTIVE on longevity research and drug pipeline.
🦠 OUTBREAKS & VIRUSES
BUNDIBUGYO VIRUS DISEASE (DRC / KENYA / NIGERIA) - MOST URGENT
- As of October 23, 2026, WHO's DON-622 confirms BVD has spread beyond the DRC to imported cases in both Kenya and Nigeria, marking new regional penetration. [1]
- Kenya's imported case involved a patient who traveled DRC-to-Uganda-to-Kenya; the patient was hospitalized and contact tracing is underway. [2]
- As of the September 25 DON-621 update, the DRC outbreak had reached a new province, Sud Ubangi in the country's northwest, adding two additional health zones to the affected total. [3]
- As of the August 14 update (DON-615), WHO described this as the largest Ebola outbreak ever reported in DRC and the fastest-expanding in history, with sustained transmission in urban and peri-urban zones. [4]
- By August 28 (DON-616), 60 health zones across six DRC provinces were affected: Bas-Uele, Haut-Uele, Ituri, North Kivu, South Kivu, and Tshopo. [5]
- The causative agent is Bundibugyo virus, a distinct Ebola species; outbreak origin traced to Mongbwalu health zone, Ituri Province, DRC, declared May 15, 2026. [6]
PNEUMONIA OF UNDETERMINED ETIOLOGY - RUSSIA
- On October 2, 2026, WHO was notified via media reports of a fatal severe pneumonia case in an employee of the Irkutsk Antiplague Research Institute of Siberia and the Far East, Russian Federation. [7]
- The etiology remains undetermined as of the October 10 DON-620 posting; WHO is seeking additional information from Russian authorities. [7]
MERS-CoV - SAUDI ARABIA
- Between January 1 and October 5, 2026, Saudi Arabia reported 8 laboratory-confirmed MERS-CoV cases including 1 death, detected across six locations: Al Jouf, Arar, Hafr Al-Batin, Riyadh, Tabuk, and one additional site. [8]
- MERS-CoV continues to circulate at low but persistent levels in the Arabian Peninsula linked to dromedary camel exposure. [8]
YELLOW FEVER - GLOBAL / AMERICAS
- From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections; transmission in the Americas that surged in 2025 carried into 2026. [9]
NIPAH VIRUS - INDIA
- On June 11, 2026, Kerala State Health Department confirmed one laboratory-confirmed Nipah virus case in Kozhikode district; the adult male developed neurological symptoms and was hospitalized on June 10. [10]
- Kozhikode has been the epicenter of prior NiV outbreaks in India; fruit bat spillover remains the suspected reservoir mechanism. [10]
ANDES HANTAVIRUS - CRUISE SHIP M/V HONDIUS
- WHO DON-611 (July 2, 2026) marked the fifth Disease Outbreak News posting on the Andes hantavirus outbreak linked to M/V Hondius; multiple countries were involved following the May 2 initial notification of severe acute respiratory illness onboard.
- CDC provided multiple daily hantavirus response briefings throughout May and June 2026, underscoring the unusual vessel-linked transmission pattern for ANDV.
LISTERIA - PREPARED MEALS (USA)
- As of the most recent CDC update (October 30, 2025), illnesses continue despite product recalls; CDC urges consumers to check refrigerators and freezers for recalled prepared meal products and discard them.
- Earlier September 26 expansions added 3 additional illnesses and 1 additional death to the prepared meals outbreak cluster.
DRUG-RESISTANT BACTERIA - USA
- A September 23, 2025 CDC report documented a dramatic increase in a dangerous class of drug-resistant bacteria, reinforcing the antimicrobial resistance threat domestically.
- An extensively drug-resistant Salmonella outbreak linked to moringa powder capsules resulted in at least 3 hospitalizations as of February 2026, with the strain resistant to multiple antibiotic classes.
ANIMAL RABIES / HUMAN EXPOSURES - USA
- CDC issued a statement September 10, 2026 flagging recent increases in animal rabies activity and associated human exposure events across the United States.
🧬 LONGEVITY & AGING
SENESCENCE AND DISC DEGENERATION: A FERROUS AGING TARGET
- A Europe PMC study in Bioactive Materials describes "ferro-aging": NOX4 enzyme drives iron-dependent oxidative stress in spinal disc cells, causing senescence and intervertebral disc degeneration.
- Researchers developed a senescent-cell-targeted iron-chelating therapy that reprograms this NOX4-associated ferro-aging pathway, offering a potential drug-free intervention for disc degeneration.
- A complementary study used cationized gelatin nanospheres to deliver RNA interference targeting mTORC1 (a key aging/senescence regulator) directly into disc tissue, reducing degeneration in preclinical models.
GLIS1 TRANSCRIPTION FACTOR AND NEURONAL SENESCENCE
- Published in Genes and Disease, a study found that the transcription factor Glis1 alleviates neuronal senescence after spinal cord injury by promoting H3K18 lactylation, an epigenetic metabolic-programming mechanism.
- H3K18 lactylation links cellular energy metabolism (lactate) to chromatin regulation, representing a newly appreciated anti-aging epigenetic pathway.
AI PREDICTS BIOLOGICAL AGE FROM FACE PHOTOGRAPHS
- A Lancet Digital Health study developed FAHR-Face, a foundation AI model that estimates biological age and health risk from facial photographs.
- The model, developed by Haugg and colleagues including Vladislav Gladyshev (a leading aging biologist), was validated across diverse cohorts; facial aging cues captured underlying systemic health signals.
- This approach could enable low-cost, non-invasive biological age screening at population scale.
OSTEOARTHRITIS: EXTRACELLULAR VESICLES AS DOUBLE-EDGED TOOLS
- A Bioactive Materials review (Yang et al.) describes extracellular vesicles (EVs) as context-dependent players in osteoarthritis: pathogenic in inflammatory joint environments but reparative when engineered for drug delivery or immune modulation.
- A DNA-adsorbing nanozyme hydrogel study (Yu et al., Bioactive Materials) reprogrammed the immuno-oxidative microenvironment in osteoarthritic cartilage, supporting stem cell-based repair by neutralizing reactive oxygen species and modulating macrophage polarization.
MYOCARDIAL REPAIR AND LYMPHANGIOGENESIS
- A tissue engineering study in Bioactive Materials (Liu et al.) showed that polymeric formulations can stimulate lymphangiogenesis, the growth of new lymphatic vessels, to aid myocardial repair after heart injury, a mechanism less explored than angiogenesis.
ANTIFIBROTIC HYDROGELS FOR SCARLESS HEALING
- A review in Bioactive Materials (Zhu et al.) catalogued antifibrotic hydrogel strategies targeting TGF-beta and related pathways to achieve scarless tissue regeneration, with applications in skin, lung, and liver fibrosis linked to aging.
💊 NEW CURES & APPROVALS
HIBSAGO (BEPIROVIRSEN) - GLAXOSMITHKLINE - HEPATITIS B
- GlaxoSmithKline received an original FDA approval (NDA 221276) for HIBSAGO, whose active ingredient is bepirovirsen, an antisense oligonucleotide targeting hepatitis B virus RNA.
- Bepirovirsen works by degrading HBV mRNA transcripts, reducing viral antigen production; it represents a new mechanism class for chronic hepatitis B, a disease affecting an estimated 257 million people globally.
JEMPERLI (DOSTARLIMAB-GXLY) - GLAXOSMITHKLINE - CANCER
- GlaxoSmithKline received a supplemental approval (BLA 761174) for Jemperli (dostarlimab-gxly), a PD-1 checkpoint inhibitor used in endometrial and mismatch-repair deficient cancers.
REBLOZYL (LUSPATERCEPT-AAMT) - CELGENE CORP - ANEMIA
- Celgene Corporation received a supplemental approval (BLA 761136) for Reblozyl (luspatercept-aamt), an erythroid maturation agent used in anemia associated with myelodysplastic syndromes and beta-thalassemia.
TOFACITINIB CITRATE - AJANTA PHARMA - AUTOIMMUNE
- Ajanta Pharma Ltd received an original approval (ANDA 219542) for generic tofacitinib citrate, a JAK inhibitor used in rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
ESTRADIOL AND LEVONORGESTREL - ZYDUS PHARMS - HORMONE THERAPY
- Zydus Pharms received an original approval (ANDA 220407) for a combination estradiol and levonorgestrel product, used in menopausal hormone therapy.
APIXABAN - TEVA PHARMACEUTICALS USA - ANTICOAGULATION
- Teva Pharmaceuticals USA received an original tentative approval (ANDA 210142) for generic apixaban, a factor Xa inhibitor used to prevent stroke, DVT, and pulmonary embolism.
🧪 CLINICAL TRIALS
ALZHEIMER'S DISEASE COHORT - FUZHOU, CHINA
- The Fuzhou Aging Brain Health Initiative (NCT07891429, registered October 23, 2026) is an observational study in Fujian Province, China, aimed at characterizing pathophysiological patterns and evolutionary trajectories of Alzheimer's disease in older adults.
- The study will establish follow-up cohorts in both general and high-risk populations to map AD biomarker progression over time.
CHINA HEALTHY AGING AND FITNESS LONGITUDINAL STUDY
- The CHALF study (NCT07881094, registered October 23, 2026) is a nationwide prospective study in China planning to recruit approximately 8,900 older adults to investigate how physical activity and physical fitness associate with healthy aging outcomes.
COGNITIVE IMPAIRMENT AND CEREBRAL SMALL VESSEL DISEASE - TMS TRIAL
- NCT07891650 (registered October 23, 2026) will enroll 160 adults with cognitive impairment linked to cerebral small vessel disease; the intervention is personalized intermittent theta burst stimulation (iTBS), a non-invasive transcranial magnetic stimulation protocol.
- Cerebral small vessel disease is one of the leading contributors to vascular dementia and age-related cognitive decline.
VIRTUAL REALITY FOR COGNITIVE AGING IN METABOLIC SYNDROME
- NCT07040748 evaluates a multimodal immersive VR intervention called Virtual-METS combining cognitive training and physical exercise in middle-aged adults with metabolic syndrome and subjective cognitive complaints.
BASE-EDITED GENE THERAPY FOR CXCR4-WHIM SYNDROME
- NCT07775313 tests base-edited hematopoietic stem and progenitor cell gene therapy for WHIM syndrome, a rare CXCR4 mutation-driven immune disorder causing severe recurrent infections across the lifespan.
NEOANTIGEN-SPECIFIC T CELL THERAPY FOR BLOOD CANCERS
- NCT06904066 is testing autologous T cells transduced with retroviral vectors expressing patient-specific neoantigen-targeting TCRs in hematologic malignancies with TP53 or RAS mutations.
MOSAIC HEXAVALENT INFLUENZA VACCINE TRIAL
- NCT06863142 evaluates FluMos-v2, an experimental mosaic hexavalent influenza vaccine, with and without the ALFQ adjuvant, in healthy adults to assess dose, safety, tolerability, and immunogenicity.
📢 PUBLIC HEALTH
LISTERIA ALERT - ONGOING, CHECK YOUR FREEZER
- CDC continues to report new illnesses despite multiple recalls in the prepared meals Listeria outbreak; consumers in all U.S. states should inspect refrigerators and freezers for recalled products and discard without eating.
SALMONELLA - MORINGA LEAF SUPPLEMENTS STILL ACTIVE
- The extensively drug-resistant Salmonella outbreak linked to moringa leaf powder capsules remains active; as of January 29, 2026, 65 people across 28 states were affected, with at least 3 hospitalizations.
CDC BIOSURVEILLANCE MILESTONE
- CDC's Traveler-Based Genomic Surveillance program surpassed 1 million voluntary air travel participants as of January 30, 2026, enhancing early detection of emerging pathogens crossing borders.
CONGENITAL SYPHILIS - 12TH CONSECUTIVE YEAR OF INCREASE
- CDC data released September 24, 2025 show U.S. newborn syphilis cases increased for the 12th straight year in 2024, underscoring a persistent maternal and child health crisis.
U.S. WITHDRAWAL FROM WHO - COMPLETED
- The United States formally completed its WHO withdrawal on January 22, 2026; WHO expressed that this decision makes both the U.S. and the world less safe, noting issues were referred to the WHO Executive Board.
LUNG CANCER MORTALITY DECLINING
- CDC's Annual Report to the Nation (September 22, 2026) shows progress against lung cancer is driving down overall U.S. cancer mortality rates.
BIOMED PULSE is an informational briefing only and does not constitute medical advice. Always consult a qualified healthcare professional for personal health decisions.
📎 Sources
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus – Democratic Republic… — WHO Disease Outbreak News
- Pneumonia of undetermined etiology - the Russian Federation — WHO Disease Outbreak News
- Middle East respiratory syndrome coronavirus - Kingdom of Saud… — WHO Disease Outbreak News
- Yellow fever - Global — WHO Disease Outbreak News
- Nipah virus disease - India — WHO Disease Outbreak News
Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20261026-02-v117 · 2026-10-26 02:01 UTC · pulse.uzylab.com